• Luminescent ATP Detection Assay Kit: Precision for Mitochond

  2026-06-30

  Discover how the Luminescent ATP Detection Assay Kit enables ultrasensitive and reproducible intracellular ATP quantification, with a special focus on mitochondrial apoptosis research. This in-depth guide explores the kit’s unique biochemical advantages and practical applications that extend beyond standard metabolism assays.

• Firefly Luciferase mRNA: Optimizing 5-moUTP Modified mRNA As

  2026-06-29

  EZ Cap™ Firefly Luciferase mRNA (5-moUTP) unlocks robust, low-immunogenicity expression for gene regulation and functional assays. This guide details best practices, protocol enhancements, and troubleshooting for maximizing data quality with this advanced in vitro transcribed mRNA.

• Agatoxin-IVA-Sensitive Calcium Channels in Cardiac Vagal Neu

  2026-06-29

  This study reveals that nicotine-induced excitation of cardiac vagal neurons is mediated specifically via agatoxin-IVA-sensitive (P-type) voltage-dependent calcium channels, impacting both presynaptic and postsynaptic mechanisms. These findings refine our understanding of calcium channel subtype contributions to cardiac autonomic regulation and suggest new precision tools for dissecting calcium-dependent signaling.

• Optimizing Immunoprecipitation with Protein A/G Magnetic Bea

  2026-06-28

  Protein A/G Magnetic Beads (SKU K1305) are engineered for antibody purification and protein interaction analysis from complex samples, providing efficient, low-background isolation of IgG antibodies. They are best suited for immunoprecipitation, co-IP, and Ch-IP workflows, but are not intended for diagnostic or clinical use.

• 3-Methyladenine in Autophagy Research: Protocols & Innovatio

  2026-06-27

  3-Methyladenine (3-MA) is a precision tool for dissecting autophagy and cell death pathways in cancer and infectious disease models. This article details hands-on workflows, advanced use-cases, and practical troubleshooting, contextualized by cutting-edge findings on cytoplasmic vacuolization cell death.

• SMYD2 Inhibition Mitigates Cisplatin-Induced Renal Fibrosis

  2026-06-26

  This study demonstrates that pharmacological inhibition of SMYD2 protects against cisplatin-induced chronic kidney disease (CKD) by reducing renal fibrosis, inflammation, and epithelial-to-mesenchymal transdifferentiation. The findings highlight SMYD2 as a potential therapeutic target for mitigating nephrotoxicity associated with cisplatin chemotherapy.

• Nystatin (Fungicidin): Advanced Workflows in Antifungal Rese

  2026-06-26

  Nystatin (Fungicidin) from APExBIO empowers researchers to address complex fungal challenges—from quantifying Candida inhibition to optimizing liposomal formulations for Aspergillus models. This article dissects applied protocols, experimental troubleshooting, and recent breakthroughs that redefine antifungal assay precision.

• Poria cocos Polysaccharides Mitigate ALD via NRF2-Regulated

  2026-06-25

  This study demonstrates that Poria cocos polysaccharides (PCP) ameliorate alcoholic liver disease (ALD) by interfering with ferroptosis through activation of the NRF2 signaling pathway. The findings highlight a mechanistic link between NRF2-mediated oxidative stress modulation and suppression of iron-dependent cell death, offering a potential new therapeutic avenue for ALD.

• IDH2-Mediated α-Ketoglutarate Dynamics in Colorectal Cancer

  2026-06-25

  This study uncovers how increased isocitrate dehydrogenase 2 (IDH2) expression in colorectal cancer cells drives metabolic reprogramming through regulation of α-ketoglutarate and HIF-1A signaling. The findings reveal a metabolic vulnerability that can be targeted to suppress tumor growth, with direct implications for hypoxia pathway research and metabolic intervention strategies.

• Regorafenib (BAY 73-4506): Applied Workflows in Tumor Resear

  2026-06-24

  Regorafenib (BAY 73-4506) stands out as a multikinase inhibitor optimized for dissecting angiogenesis, tumor proliferation, and metastasis in advanced cancer biology research. This article translates new mechanistic insights into practical, protocol-driven strategies for both in vitro and in vivo studies—empowering researchers with actionable solutions for experimental design and troubleshooting.

• Captopril: Precision ACE Inhibitor for Hypertension & Oncolo

  2026-06-23

  Captopril, a high-purity ACE inhibitor, offers benchmark performance for hypertension and oncology research by enabling reproducible modulation of the RAAS and bradykinin pathways. Discover how integrated workflows and troubleshooting strategies maximize experimental reliability when using this APExBIO reagent.

• Chloroquine Diphosphate: Enhancing Autophagy and Sensitizati

  2026-06-23

  Chloroquine diphosphate is a cornerstone in autophagy assays, uniquely bridging cancer research and therapy sensitization. This article translates recent mechanistic discoveries into actionable workflows and troubleshooting strategies to maximize reproducibility and impact.

• Baicalin for KEAP1-NRF2/HO-1 Pathway Modulation in Research

  2026-06-22

  Baicalin’s precise modulation of KEAP1-NRF2/HO-1 and TGF-β1/p-Smad3 pathways enables transformative advances in neuroplasticity and cancer research. APExBIO’s high-purity Baicalin streamlines experimental workflows, offering reproducibility and actionable troubleshooting for sensitive models like adult amblyopia.

• LY2109761: TGF-β Receptor I/II Dual Inhibitor in Translation

  2026-06-22

  LY2109761 enables precise inhibition of the TGF-β signaling pathway, empowering researchers to dissect mechanisms of tumor progression, metastasis, and fibrosis. Explore workflow optimizations, troubleshooting, and advanced applications—anchored by recent evidence and best practices for robust results.

• (S)-Mephenytoin as a CYP2C19 Substrate in Intestinal Organoi

  2026-06-21

  (S)-Mephenytoin enables precise, reproducible assessment of CYP2C19-mediated drug metabolism in hiPSC-derived intestinal organoids, surpassing conventional cell-based models. This article details experimental workflows, actionable protocol parameters, and troubleshooting strategies, empowering researchers to optimize in vitro pharmacokinetic studies with APExBIO’s high-purity substrate.

452 records 13/31 page Previous Next First page 上5页 1112131415 下5页 Last page